Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients
Cyxone (publ.) announced today it has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients. The oral treatment is intended to prevent the progression to acute respiratory distress symptoms (ARDS) caused by virus-related overactivation of the immune system. Preliminary results are expected in the third quarter of 2021.Most individuals infected with Covid-19 experience only mild symptoms. However, in some patients there is a risk that the immune system overreacts, triggering a